FC
GSK icon

Financial Consulate’s GSK GSK Stock Holding History

Financial Consulate’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Buy
587
+47
+9% +$2.49K ﹤0.01% 440
2026
Q1 		$29.8K Buy
540
+199
+58% +$10.8K ﹤0.01% 413
2025
Q4 		$16.7K Buy
341
+215
+171% +$10K ﹤0.01% 506
2025
Q3 		$5.44K Buy
+126
New +$4.92K ﹤0.01% 642

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM

Financial Consulate's GSK Position: Q2 2026 in Review

Financial Consulate increased its GSK (GSK) stake by 8.7% in Q2 2026, buying an estimated $2.49K and bringing the position to 587 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #440.

Financial Consulate first reported a position in GSK in Q3 2025 and has held it in 4 quarters since. 296 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Financial Consulate held 587 shares of GSK worth $30.8K as of Q2 2026.
  • Financial Consulate bought 47 GSK shares in Q2 2026, an estimated $2.49K.
  • GSK made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #440 holding.
  • Financial Consulate first reported a position in GSK in Q3 2025 and has held it in 4 quarters since.
  • 296 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.